View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 24, 2018updated 12 Jul 2022 1:12pm

Nightstar reports positive preliminary results from XIRIUS trial

Nightstar Therapeutics has reported positive preliminary safety and efficacy results from the XIRIUS trial, a Phase l/ll study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa (XLRP) in patients with RPGR mutation.

Nightstar Therapeutics has reported positive preliminary safety and efficacy results from the XIRIUS trial, a Phase l/ll study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa (XLRP) in patients with RPGR mutation.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The results are based on the dose-escalation phase of the XIRIUS trial, an open-label, dose-ranging, single-eye study, currently being conducted at sites in the US and the UK.

They include data from the one-month follow-up for the first five cohorts of patients.

The results show preliminary efficacy signals observed in 3/3 patients in cohort 3, and 2/6 patients in cohorts 4 and 5.

Significant improvements were observed in overall macula sensitivity, central 16 macula sensitivity and number of improved macula.

NSR-RPGR was also found to be well-tolerated, with no dose-limiting toxicities or serious treatment-related adverse events.

Nightstar Therapeutics chief development officer Tuyen Ong said: “We initiated this study last year, with the anticipation of demonstrating safety and stabilisation of disease with NSR-RPGR, our codon-optimised gene therapy for XLRP.

“Based on the preliminary findings of improved visual function as measured by microperimetry, we have established early proof of concept in XLRP, our second clinical programme.”

“Based on the preliminary findings of improved visual function as measured by microperimetry, we have established early proof of concept in XLRP, our second clinical programme.”

Last month, Nightstar completed patient enrolment in the XIRIUS trial, which comprises six cohorts of three patients each for a total of 18 adult patients.

During the trial, each patient received a single sub-retinal injection of NSR-RPGR.

One-year follow-up data on all 18 patients from the dose-escalation phase of the XIRIUS trial is scheduled to be released next year.

The trial also includes an expansion phase, which is planned to begin in the last quarter of this year.

The expansion study is expected to enrol around 30 adult and paediatric patients to administer a therapeutic dose confirmed by the dose-escalation phase.

It will also include a low-dose control group of around 15 patients. Preliminary efficacy results from this phase are expected to be available next year, with one-year follow-up data expected to be available in 2020.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena